Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker ORKA
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Arjun Agarwal Senior Vice President, Finance | ORKA Oruka Therapeutics, Inc. | Sale | 100 | $107.00 | $10.7K Sale | Form 4 ↗ |
| Nov 12, 2026 | Arjun Agarwal Senior Vice President, Finance | ORKA Oruka Therapeutics, Inc. | Sale | 958 | $106.18 | $101.7K Sale | Form 4 ↗ |
| Nov 12, 2026 | Arjun Agarwal Senior Vice President, Finance | ORKA Oruka Therapeutics, Inc. | Sale | 6,842 | $105.28 | $720.3K Sale | Form 4 ↗ |
| Nov 12, 2026 | Arjun Agarwal Senior Vice President, Finance | ORKA Oruka Therapeutics, Inc. | Sale | 799 | $104.25 | $83.3K Sale | Form 4 ↗ |
| Nov 12, 2026 | Arjun Agarwal Senior Vice President, Finance | ORKA Oruka Therapeutics, Inc. | Sale | 801 | $103.16 | $82.6K Sale | Form 4 ↗ |
| Nov 12, 2026 | Arjun Agarwal Senior Vice President, Finance | ORKA Oruka Therapeutics, Inc. | Sale | 500 | $101.98 | $51.0K Sale | Form 4 ↗ |
| Nov 12, 2026 | Kristine M. Ball Director | ORKA Oruka Therapeutics, Inc. | Sale | 200 | $106.99 | $21.4K Sale | Form 4 ↗ |
| Nov 12, 2026 | Kristine M. Ball Director | ORKA Oruka Therapeutics, Inc. | Sale | 2,500 | $106.05 | $265.1K Sale | Form 4 ↗ |
| Nov 12, 2026 | Kristine M. Ball Director | ORKA Oruka Therapeutics, Inc. | Sale | 10,765 | $105.31 | $1.1M Sale | Form 4 ↗ |
| Nov 12, 2026 | Kristine M. Ball Director | ORKA Oruka Therapeutics, Inc. | Sale | 2,039 | $104.16 | $212.4K Sale | Form 4 ↗ |
| Nov 12, 2026 | Kristine M. Ball Director | ORKA Oruka Therapeutics, Inc. | Sale | 1,300 | $103.09 | $134.0K Sale | Form 4 ↗ |
| Nov 12, 2026 | Kristine M. Ball Director | ORKA Oruka Therapeutics, Inc. | Sale | 1,196 | $102.10 | $122.1K Sale | Form 4 ↗ |
| Nov 2, 2026 | Lawrence Otto Klein Chief Executive Officer, Director | ORKA Oruka Therapeutics, Inc. | Sale | 300 | $98.40 | $29.5K Sale | Form 4 ↗ |
| Nov 2, 2026 | Lawrence Otto Klein Chief Executive Officer, Director | ORKA Oruka Therapeutics, Inc. | Sale | 756 | $97.45 | $73.7K Sale | Form 4 ↗ |
| Nov 2, 2026 | Lawrence Otto Klein Chief Executive Officer, Director | ORKA Oruka Therapeutics, Inc. | Sale | 2,442 | $96.70 | $236.1K Sale | Form 4 ↗ |
| Nov 2, 2026 | Lawrence Otto Klein Chief Executive Officer, Director | ORKA Oruka Therapeutics, Inc. | Sale | 15,036 | $95.64 | $1.4M Sale | Form 4 ↗ |
| Nov 2, 2026 | Lawrence Otto Klein Chief Executive Officer, Director | ORKA Oruka Therapeutics, Inc. | Sale | 6,466 | $94.77 | $612.8K Sale | Form 4 ↗ |
| Oct 20, 2026 | Paul T. Quinlan General Counsel | ORKA Oruka Therapeutics, Inc. | Sale | 3,000 | $79.49 | $238.5K Sale | Form 4 ↗ |
| Oct 20, 2026 | Paul T. Quinlan General Counsel | ORKA Oruka Therapeutics, Inc. | Sale | 4,100 | $78.79 | $323.0K Sale | Form 4 ↗ |
| Oct 20, 2026 | Paul T. Quinlan General Counsel | ORKA Oruka Therapeutics, Inc. | Sale | 1,000 | $77.21 | $77.2K Sale | Form 4 ↗ |
| Oct 20, 2026 | Paul T. Quinlan General Counsel | ORKA Oruka Therapeutics, Inc. | Sale | 500 | $76.12 | $38.1K Sale | Form 4 ↗ |
| Oct 20, 2026 | Paul T. Quinlan General Counsel | ORKA Oruka Therapeutics, Inc. | Sale | 400 | $74.90 | $30.0K Sale | Form 4 ↗ |
| Sep 21, 2026 | Arjun Agarwal Senior Vice President, Finance | ORKA Oruka Therapeutics, Inc. | Sale | 533 | $95.75 | $51.0K Sale | Form 4 ↗ |
| Sep 21, 2026 | Paul T. Quinlan General Counsel | ORKA Oruka Therapeutics, Inc. | Sale | 2,667 | $95.31 | $254.2K Sale | Form 4 ↗ |
| Sep 21, 2026 | Paul T. Quinlan General Counsel | ORKA Oruka Therapeutics, Inc. | Sale | 601 | $94.44 | $56.8K Sale | Form 4 ↗ |
| Sep 21, 2026 | Paul T. Quinlan General Counsel | ORKA Oruka Therapeutics, Inc. | Sale | 3,832 | $93.32 | $357.6K Sale | Form 4 ↗ |
| Sep 21, 2026 | Paul T. Quinlan General Counsel | ORKA Oruka Therapeutics, Inc. | Sale | 2,900 | $92.37 | $267.9K Sale | Form 4 ↗ |
| Sep 15, 2026 | Joana Goncalves Chief Medical Officer | ORKA Oruka Therapeutics, Inc. | Sale | 947 | $95.71 | $90.6K Sale | Form 4 ↗ |
| Sep 15, 2026 | Joana Goncalves Chief Medical Officer | ORKA Oruka Therapeutics, Inc. | Sale | 100 | $94.22 | $9,422 Sale | Form 4 ↗ |
| Sep 15, 2026 | Joana Goncalves Chief Medical Officer | ORKA Oruka Therapeutics, Inc. | Sale | 1,366 | $92.99 | $127.0K Sale | Form 4 ↗ |
| Sep 15, 2026 | Joana Goncalves Chief Medical Officer | ORKA Oruka Therapeutics, Inc. | Sale | 3,150 | $92.03 | $289.9K Sale | Form 4 ↗ |
| Sep 15, 2026 | Joana Goncalves Chief Medical Officer | ORKA Oruka Therapeutics, Inc. | Sale | 2,384 | $91.10 | $217.2K Sale | Form 4 ↗ |
| Sep 15, 2026 | Arjun Agarwal Senior Vice President, Finance | ORKA Oruka Therapeutics, Inc. | Sale | 560 | $95.71 | $53.6K Sale | Form 4 ↗ |
| Sep 15, 2026 | Lawrence Otto Klein Chief Executive Officer, Director | ORKA Oruka Therapeutics, Inc. | Sale | 2,452 | $95.71 | $234.7K Sale | Form 4 ↗ |
| Sep 15, 2026 | Paul T. Quinlan General Counsel | ORKA Oruka Therapeutics, Inc. | Sale | 1,039 | $95.71 | $99.4K Sale | Form 4 ↗ |
| Sep 15, 2026 | Laura Lee Sandler Chief Operating Officer | ORKA Oruka Therapeutics, Inc. | Sale | 906 | $95.71 | $86.7K Sale | Form 4 ↗ |
| Sep 11, 2026 | Arjun Agarwal Senior Vice President, Finance | ORKA Oruka Therapeutics, Inc. | Sale | 200 | $94.02 | $18.8K Sale | Form 4 ↗ |
| Sep 11, 2026 | Arjun Agarwal Senior Vice President, Finance | ORKA Oruka Therapeutics, Inc. | Sale | 2,208 | $93.26 | $205.9K Sale | Form 4 ↗ |
| Sep 11, 2026 | Arjun Agarwal Senior Vice President, Finance | ORKA Oruka Therapeutics, Inc. | Sale | 4,051 | $92.41 | $374.4K Sale | Form 4 ↗ |
| Sep 11, 2026 | Arjun Agarwal Senior Vice President, Finance | ORKA Oruka Therapeutics, Inc. | Sale | 3,000 | $91.11 | $273.3K Sale | Form 4 ↗ |
| Sep 1, 2026 | Laura Lee Sandler Chief Operating Officer | ORKA Oruka Therapeutics, Inc. | Sale | 4,000 | $92.01 | $368.0K Sale | Form 4 ↗ |
| Sep 1, 2026 | Laura Lee Sandler Chief Operating Officer | ORKA Oruka Therapeutics, Inc. | Sale | 1,000 | $91.05 | $91.0K Sale | Form 4 ↗ |
| Sep 1, 2026 | Lawrence Otto Klein Chief Executive Officer, Director | ORKA Oruka Therapeutics, Inc. | Sale | 4,800 | $92.44 | $443.7K Sale | Form 4 ↗ |
| Sep 1, 2026 | Lawrence Otto Klein Chief Executive Officer, Director | ORKA Oruka Therapeutics, Inc. | Sale | 63,596 | $91.90 | $5.8M Sale | Form 4 ↗ |
| Sep 1, 2026 | Lawrence Otto Klein Chief Executive Officer, Director | ORKA Oruka Therapeutics, Inc. | Sale | 6,604 | $90.79 | $599.6K Sale | Form 4 ↗ |
| Aug 17, 2026 | Joana Goncalves Chief Medical Officer | ORKA Oruka Therapeutics, Inc. | Sale | 2,480 | $112.56 | $279.1K Sale | Form 4 ↗ |
| Aug 17, 2026 | Joana Goncalves Chief Medical Officer | ORKA Oruka Therapeutics, Inc. | Sale | 3,320 | $112.01 | $371.9K Sale | Form 4 ↗ |
| Aug 17, 2026 | Joana Goncalves Chief Medical Officer | ORKA Oruka Therapeutics, Inc. | Sale | 300 | $110.52 | $33.2K Sale | Form 4 ↗ |
| Aug 17, 2026 | Joana Goncalves Chief Medical Officer | ORKA Oruka Therapeutics, Inc. | Sale | 900 | $109.65 | $98.7K Sale | Form 4 ↗ |
| Aug 14, 2026 | Paul T. Quinlan General Counsel | ORKA Oruka Therapeutics, Inc. | Sale | 3,847 | $111.14 | $427.6K Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:50 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances